- Home
- MNPR vs STIM Comparison
MNPR vs STIM Comparison
Compare MNPR & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- STIM
- Stock Information
- Founded
- MNPR 2014
- STIM 2003
- Country
- MNPR United States
- STIM United States
- Employees
- MNPR N/A
- STIM N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- STIM Medical/Dental Instruments
- Sector
- MNPR Health Care
- STIM Health Care
- Exchange
- MNPR Nasdaq
- STIM Nasdaq
- Market Cap
- MNPR 248.8M
- STIM 224.8M
- IPO Year
- MNPR 2019
- STIM 2018
- Fundamental
- Price
- MNPR $44.21
- STIM $3.23
- Analyst Decision
- MNPR Strong Buy
- STIM Strong Buy
- Analyst Count
- MNPR 10
- STIM 2
- Target Price
- MNPR $66.56
- STIM $7.00
- AVG Volume (30 Days)
- MNPR 38.8K
- STIM 1.5M
- Earning Date
- MNPR 11-07-2025
- STIM 08-05-2025
- Dividend Yield
- MNPR N/A
- STIM N/A
- EPS Growth
- MNPR N/A
- STIM N/A
- EPS
- MNPR N/A
- STIM N/A
- Revenue
- MNPR N/A
- STIM $111,106,000.00
- Revenue This Year
- MNPR N/A
- STIM $105.70
- Revenue Next Year
- MNPR N/A
- STIM $11.77
- P/E Ratio
- MNPR N/A
- STIM N/A
- Revenue Growth
- MNPR N/A
- STIM 54.17
- 52 Week Low
- MNPR $2.29
- STIM $0.52
- 52 Week High
- MNPR $54.30
- STIM $5.92
- Technical
- Relative Strength Index (RSI)
- MNPR 65.29
- STIM 39.37
- Support Level
- MNPR $32.77
- STIM $3.07
- Resistance Level
- MNPR $36.49
- STIM $3.43
- Average True Range (ATR)
- MNPR 2.93
- STIM 0.26
- MACD
- MNPR 1.14
- STIM -0.01
- Stochastic Oscillator
- MNPR 99.97
- STIM 28.75
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About STIM Neuronetics Inc.
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.